Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies
HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed...






